US 12,310,979 B2
Inhalable formulation of fluticasone propionate and albuterol sulfate
Brian Paul O′Neill, Waterford (IE); Hardik Kirtikumar Shah, Waterford (IE); Julian Alexander Blair, Waterford (IE); Chris David Edlin, Waterford (IE); and Shane Michael McKeon, Waterford (IE)
Assigned to NORTON (WATERFORD) LIMITED, Waterford (IE)
Filed by NORTON (WATERFORD) LIMITED, Waterford (IE)
Filed on Apr. 25, 2023, as Appl. No. 18/139,031.
Application 18/139,031 is a continuation of application No. 17/410,774, filed on Aug. 24, 2021, granted, now 11,638,710.
Application 17/410,774 is a continuation of application No. PCT/EP2021/072718, filed on Aug. 16, 2021.
Claims priority of application No. 2012742 (GB), filed on Aug. 14, 2020.
Prior Publication US 2023/0255983 A1, Aug. 17, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/569 (2006.01); A61K 9/00 (2006.01); A61K 9/16 (2006.01); A61K 31/137 (2006.01); A61K 47/26 (2006.01); A61M 15/00 (2006.01); A61P 11/08 (2006.01)
CPC A61K 31/569 (2013.01) [A61K 9/0075 (2013.01); A61K 9/1623 (2013.01); A61K 9/1694 (2013.01); A61K 31/137 (2013.01); A61K 47/26 (2013.01); A61M 15/0008 (2014.02); A61M 15/0065 (2013.01); A61M 2202/064 (2013.01); A61M 2206/16 (2013.01)] 3 Claims
 
1. A method for the treatment of acute exacerbations of asthma or COPD in a subject in need thereof, comprising administering to the subject pro re nata rescue medication of a dry powder inhalable formulation consisting of fluticasone propionate, albuterol sulfate and α-lactose monohydrate, wherein a total administered daily dose of fluticasone propionate does not exceed 1,000 μg.